Cancer

Mouse studies suggest combining DIABLO mimetics with an oncolytic vesicular stomatitis virus (VSV) could help treat rhabdomyosarcoma. In an orthotopic xenograft mouse model of the cancer, the DIABLO mimetic LCL161 plus an oncolytic VSV increased survival compared with either agent alone. Next steps could include testing the effects of the combination therapy on tumor growth in rhabdomyosarcoma models.

Novartis AG has LCL161, an IAP antagonist, in Phase II testing for leukemia and multiple myeloma (MM), Phase I/II testing for breast cancer and Phase I testing for pancreatic cancer...